Phase I, Open-Label Study With Dendritic Cell Therapy (MesoPher) In Combination With Ex-tended-Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma
Latest Information Update: 29 Apr 2025
At a glance
- Drugs Autologous dendritic cell vaccine Amphera (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- Acronyms ENSURE
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 25 Apr 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 13 Sep 2022 Trial design presented at the 47th European Society for Medical Oncology Congress